This C5 inhibitor has been evaluated for paroxysmal nocturnal hemoglobinuria (PNH), CD55-deficient protein-losing enteropathy, and CHAPLE disease [37,38]. The gene discussed is CD55; the disease is paroxysmal nocturnal hemoglobinuria.